Neurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease

November 23, 2016 9:50 AM EST
Get Alerts NTRP Hot Sheet
Trade NTRP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Neurotrope, Inc. (OTC: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, issued a statement on Eli Lilly's (NYSE: LLY) experimental drug solanezumab. Lilly stated that, based upon results from its recent Phase 3 clinical trial, solanezumab failed to improve cognition of patients with mild Alzheimer's disease.

Dr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer stated' "I deeply regret the news released today that Lilly's latest trial of its leading Alzheimer's drug candidate has failed. Lilly's dedication and persistence to finding a cure for this devastating affliction deserves everyone's admiration and gratitude.

Repeated attempts to treat or even slow the relentless progression of Alzheimer's disease by targeting the red flag in patient's brains called amyloid plaques have continued to lead to such disappointing outcomes.

Neurotrope has focused all of its resources on regenerative medicine that would replace the lost synaptic networks that are so consistently associated with the breakdown of human cognitive functions. Bryostatin, a drug that induces growth of new networks to replace those that have degenerated while also degrading plaques and tau tangles, may also address the red flags of this scourge threatening increasing numbers of the world's aging populations. At Neurotrope, we believe that treating Alzheimer's disease is a daunting challenge that will need to be treated by a drug with multi modal efficacy. We believe that our drug bryotstatin may be the drug. The top line results of our Phase 2 study with 148 patients is expected to be announced in April 2017.

We hope, at that time, that a new therapy will be viewed as a possible future treatment for this disease."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Related Entities

Carl Icahn

Add Your Comment